Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce progress in its regulatory strategy for its first commercial product, the pre-surgical triage test. Highlights Initial pre-submission meeting held with the U.S. Food & Drug Administration (FDA) where CLEO outlined its submission framework and…
Boss Energy Limited (ASX: BOE; OTCQX: BQSSF) is pleased to announce high-grade drill results on theGould’s Dam satellite deposit.…
The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment. Coming in only after cardiovascular…
Sarama Resources Ltd. (“Sarama” or the “Company”) (ASX:SRR, TSX- V:SWA) is pleased to report that on 25 June 2024,…
Overview Cardiol Therapeutics. (NASDAQ:CRDL,TSX:CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory…
Regardless of how the gold price is doing, the top gold-mining companies are always making moves. Right now, the…
(TheNewswire) Company now gearing up and actively enhancing its supply chain of fully integrated electrolyzers with capacities up to…
For a long time, most of the world’s lithium was produced by an oligopoly of producers often referred to…
Investor Insight Horizon Minerals’ near-term cash-flow potential and its significant land package in the prolific Western Australian goldfields with…